Home > News > Mednax Can Sustain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
October 25th, 2010
Mednax Can Sustain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
Abstract:
Morgan Keegan said that its EPS estimate of $1.05 versus $1.03 in the prior year period is in line with the First Call consensus, adding, "We are confident that the company's earnings will at least meet Mednax's guidance of $1.03-$1.07."
Mednax closed Friday at $56.96.
Source:
benzinga.com
| Related News Press |
News and information
Quantum computer improves AI predictions April 17th, 2026
Flexible sensor gains sensitivity under pressure April 17th, 2026
A reusable chip for particulate matter sensing April 17th, 2026
Detecting vibrational quantum beating in the predissociation dynamics of SF6 using time-resolved photoelectron spectroscopy April 17th, 2026
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||